Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report issued on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a buy rating and issued a $7.00 target price on shares of Aptose Biosciences in a research report on Friday, June 14th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and an average target price of $9.00.

Aptose Biosciences Price Performance

Shares of APTO stock opened at $0.41 on Thursday. Aptose Biosciences has a 1 year low of $0.33 and a 1 year high of $3.32. The company has a market cap of $7.34 million, a PE ratio of -0.07 and a beta of 1.25. The stock’s 50 day simple moving average is $0.45 and its two-hundred day simple moving average is $0.88.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.15. Equities research analysts expect that Aptose Biosciences will post -2.62 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC purchased a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences as of its most recent SEC filing. 26.62% of the stock is owned by institutional investors and hedge funds.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.